Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vivus closes enrollment in Equate obesity study
The Equate study has enrolled over 700 patients with body mass index ranging from 30 to 45 in 35 clinical sites. Patients in the Equate study will undergo
The Equate study has enrolled over 700 patients with body mass index ranging from 30 to 45 in 35 clinical sites. Patients in the Equate study will undergo
The collaboration integrates the NCCN Clinical Practice Guidelines in Oncology, Drugs and Biologics Compendium and Standard Chemotherapy Order Templates into the Cerner Millennium healthcare computing platform. NCCN’s Guidelines
Upon the closing of the transaction, anticipated to be within the next 120 days, Misonix will receive approximately $1.5 million at closing for the value of its equity
The study of AFN-1252 will evaluate the safety, tolerability and pharmacokinetics of a single escalating oral dose. Affinium believes that AFN-1252 will provide patients and their doctors a
DAG Ventures led the round, which included investments from previous investors Kleiner Perkins Caufield & Byers, New Science Ventures, Integral Capital Partners, Aperture Venture Partners and Cross Creek
DM-99 is a biological product with a well established safety profile that is being studied by DiaMedica for a novel use as a treatment for type 2 diabetes.
The acquisition will complement Cardinal Health’s infection prevention offerings by adding a differentiated and proven product line to the company’s Medical Products and Technologies segment. Cardinal Health plans
The test measures for a substance known as HE4, which many studies have shown can be elevated in epithelial ovarian cancers. The test is intended to be used
The Canadian Intellectual Property Office has granted a patent for the process, formulation and use claims to a mixed micellar pharmaceutical formulation for buccal administration. The National Institute
Bioniche plans to start a Phase III clinical trial comparing Urocidin, to the current standard therapy in patients with non-muscle-invasive bladder cancer at high risk of recurrence or